跳至主要内容
临床试验/NCT04487405
NCT04487405终止不适用

A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

Aspira Women's Health9 个研究点 分布在 1 个国家目标入组 721 人开始时间: 2020年6月25日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
721
试验地点
9
主要终点
OVAnex

研究概览

简要总结

The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patient, 18 years of age or older diagnosed with an ovarian adnexal mass, or in follow-up due to the presence of BRCA1/2 and other germline DNA variants.
  • Patient reviewed, understood, and provided the PI with written informed consent to allow blood specimen to be used for research and release of medical information.

排除标准

  • Patient is less than 18 years of age
  • Patient is not being treated in the U.S.

结局指标

主要结局

OVAnex

时间窗: 12 months

OVAnex is a multivariate index assay assessing ovarian cancer risk. The Ovanex MIA uses seven biomarkers with a stepwise algorithm to generate a risk score which ranges from 0 to 20.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验